Related Experiment Video
Updated: May 28, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Clinical Features, Complications, and Treatment Outcomes of Pediatric Pars Planitis Cases in a Tertiary Referral
Duygu Gülmez Sevim1, Hidayet Sener1, Furkan Ozer2
1Department of Ophthalmology, Erciyes University Medical Faculty, Kayseri, Turkey.
Insights
Pediatric pars planitis (PPP) treatment with immunosuppressants effectively reduces inflammation and improves vision. Early intervention is key for optimal visual outcomes in children with PPP.
Area of Science:
- Ophthalmology
- Pediatric Ophthalmology
- Uveitis Management
Background:
- Pediatric pars planitis (PPP) is a form of intermediate uveitis affecting children.
- Understanding its clinical course and treatment outcomes is crucial for effective management.
Purpose of the Study:
- To detail the clinical manifestations, ocular complications, and treatment results of pediatric pars planitis (PPP).
Main Methods:
- Retrospective study of 28 children (51 eyes) aged 16 or younger.
- Data collected included visual acuity, inflammation grades, macular thickness, and treatment approaches.
- Analysis of outcomes at 3, 6, 9, and 12 months post-treatment.
Main Results:
- Significant visual acuity improvement within the first 3 months (p=0.025).
- Marked reduction in anterior chamber cells and vitritis grade after treatment.
- Initial macular edema present in 27% of eyes, with 57% showing reduced central macular thickness post-treatment.
Conclusions:
- Immunosuppressive therapy effectively controls intraocular inflammation in pediatric pars planitis.
- Treatment should focus on inflammation, macular edema, and papillitis.
- Early diagnosis and aggressive treatment are vital for preserving visual prognosis.
Purpose:
To present the clinical manifestations, ocular complications and treatment results of pediatric pars planitis (PPP).
Methods:
This retrospective clinical study was conducted at a tertiary care center and included 28 children (51 eyes) aged 16 years or younger. Visual acuity (VA), anterior chamber cell (ACC) grade, vitritis grade, central macular thickness (CMT), fundus fluorescein angiography (FFA) score, treatment approach, complications, and relapse rate were recorded. All data were analyzed for baseline, third month, sixth month, ninth month, and twelfth month.
Results:
The mean or median follow-up duration was 12 months. A total of twenty patients (71%) were administered Methotrexate (MTX) and the mean MTX dosage was 8.6 ± 1.1 mg. Ten patients (35%) were administered corticosteroid, and the mean dosage was 29.6 ± 4.2 mg. Adalimumab was administered to 16 patients (57%). There was a significant improvement in VA (-0.068, p = 0.025) during the first 3 months of follow-up. There were no significant changes in the VA during the subsequent follow-up periods. ACC grade decreased significantly in the third month (-0.765, p < 0.001), while vitritis grade decreased significantly in the sixth month (-0.502, p < 0.001). There was no significant change in CMT in all study eyes during the follow-up periods. However, there was macular edema in 14 eyes (27%) in baseline examination. After treatment, CMT was lower than 250 µm in 8 eyes (57%) in the last follow-up.
Conclusion:
Immunosuppressive therapy is effective in suppressing intraocular inflammation. Treatment should be aimed at controlling inflammation, macular edema, and papillitis. Early diagnosis and aggressive treatment are important for a good visual prognosis.
Related Concept Videos
Tonsillitis II: Management
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Angle Closure Glaucoma: Treatment
Tertiary Healthcare System
Tonsillitis I: Introduction
Etiology
Three primary contributing factors have been identified.
Pneumonia III: Complications and Assessment

